This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boyd, D. D. Articles by Gallick, G. E. Search for Related Content PubMed PubMed Citation Articles by Boyd, D. D. Articles by Gallick, G. E.

Combination of an Src Kinase Inhibitor with a Novel Pharmacological Antagonist of the Urokinase Receptor Diminishes in Vitro Colon Cancer Invasiveness

¹ Department of Cancer Biology, M. D. Anderson Cancer Center, Houston, Texas, and ² Technical University of Munich, Munich, Germany

Purpose: The urokinase-type plasminogen activator receptor (u-PAR) contributes to colon cancer invasion and metastases. We have shown previously that u-PAR expression in colon cancer is driven by the Src tyrosine kinase. In the current study, we determined the ability of PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a Src kinase inhibitor, to reduce u-PAR expression and colon cancer invasion.

Experimental Design: Western blotting, Northern blotting, and u-PAR promoter-reporter assays were performed to determine whether PP2 represses u-PAR expression. In vitro invasion assays were used to determine whether this kinase inhibitor, with or without a novel u-PAR antagonist, diminished cultured colon cancer invasiveness.

Results: A constitutively active c-Src increased in vitro invasiveness of SW480 cells, whereas HT-29 cells expressing antisense c-Src showed diminished invasiveness, validating c-Src as a target for low molecular weight compound(s). The Src inhibitor PP2 reduced u-PAR transcription in HT-29 cells over the concentration range that blocked Src kinase activity. PP2 also reduced u-PAR protein amounts in three other colon cancer cell lines with modest to high constitutive Src activity. Treatment of HT-29 cells and 2C8 cells (a SW480 clone expressing a constitutively active Src) with PP2 diminished their in vitro invasiveness. Furthermore, combination of the Src inhibitor with a novel u-PAR peptide antagonist (NI-5.12) proved superior to the individual agents in suppressing invasiveness.

Conclusions: A c-Src kinase inhibitor represses u-PAR expression and, alone or in combination with a u-PAR antagonist, diminishes colon cancer invasiveness. Thus, concurrent targeting of c-Src expression and pharmacological blockade of the u-PAR may represent a novel means of controlling colon cancer spread.

This article has been cited by other articles:

				A. Spreafico, S. Schenone, T. Serchi, M. Orlandini, A. Angelucci, D. Magrini, G. Bernardini, G. Collodel, A. Di Stefano, C. Tintori, et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells FASEB J, May 1, 2008; 22(5): 1560 - 1571. [Abstract] [Full Text] [PDF]

				M. Spitzner, J. R. Martins, R. B. Soria, J. Ousingsawat, K. Scheidt, R. Schreiber, and K. Kunzelmann Eag1 and Bestrophin 1 Are Up-regulated in Fast-growing Colonic Cancer Cells J. Biol. Chem., March 21, 2008; 283(12): 7421 - 7428. [Abstract] [Full Text] [PDF]

				J. H. Leupold, I. Asangani, G. D. Maurer, E. Lengyel, S. Post, and H. Allgayer Src Induces Urokinase Receptor Gene Expression and Invasion/Intravasation via Activator Protein-1/p-c-Jun in Colorectal Cancer Mol. Cancer Res., May 1, 2007; 5(5): 485 - 496. [Abstract] [Full Text] [PDF]

				L. Y. Han, C. N. Landen, J. G. Trevino, J. Halder, Y. G. Lin, A. A. Kamat, T.-J. Kim, W. M. Merritt, R. L. Coleman, D. M. Gershenson, et al. Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Res., September 1, 2006; 66(17): 8633 - 8639. [Abstract] [Full Text] [PDF]

				V. G. Brunton, E. Avizienyte, V. J. Fincham, B. Serrels, C. A. Metcalf III, T. K. Sawyer, and M. C. Frame Identification of Src-Specific Phosphorylation Site on Focal Adhesion Kinase: Dissection of the Role of Src SH2 and Catalytic Functions and Their Consequences for Tumor Cell Behavior Cancer Res., February 15, 2005; 65(4): 1335 - 1342. [Abstract] [Full Text] [PDF]

				A. Angers-Loustau, R. Hering, T. E. Werbowetski, D. R. Kaplan, and R. F. Del Maestro Src Regulates Actin Dynamics and Invasion of Malignant Glial Cells in Three Dimensions Mol. Cancer Res., November 1, 2004; 2(11): 595 - 605. [Abstract] [Full Text] [PDF]